165 related articles for article (PubMed ID: 33884961)
1. In vivo visualization of PARP inhibitor pharmacodynamics.
McDonald ES; Pantel AR; Shah PD; Farwell MD; Clark AS; Doot RK; Pryma DA; Carlin SD
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884961
[TBL] [Abstract][Full Text] [Related]
2. [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study.
Pantel AR; Gitto SB; Makvandi M; Kim H; Medvedv S; Weeks JK; Torigian DA; Hsieh CJ; Ferman B; Latif NA; Tanyi JL; Martin LP; Lanzo SM; Liu F; Cao Q; Mills GB; Doot RK; Mankoff DA; Mach RH; Lin LL; Simpkins F
Clin Cancer Res; 2023 Apr; 29(8):1515-1527. PubMed ID: 36441795
[TBL] [Abstract][Full Text] [Related]
3. Molecular imaging of PARP in cancer: state-of-the-art.
Filippi L; Urso L; Frantellizzi V; Marzo K; Marzola MC; Schillaci O; Evangelista L
Expert Rev Mol Diagn; 2023; 23(12):1167-1174. PubMed ID: 38009232
[TBL] [Abstract][Full Text] [Related]
4. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
5. Pilot Study: PARP1 Imaging in Advanced Prostate Cancer.
Dehdashti F; Reimers MA; Shoghi KI; Chen DL; Luo J; Rogers B; Pachynski RK; Sreekumar S; Weimholt C; Zhou D
Mol Imaging Biol; 2022 Dec; 24(6):853-861. PubMed ID: 35701722
[TBL] [Abstract][Full Text] [Related]
6. The Development of
Lee HS; Schwarz SW; Schubert EK; Chen DL; Doot RK; Makvandi M; Lin LL; McDonald ES; Mankoff DA; Mach RH
Radiol Imaging Cancer; 2022 Jan; 4(1):e210070. PubMed ID: 35089089
[TBL] [Abstract][Full Text] [Related]
7. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.
Michel LS; Dyroff S; Brooks FJ; Spayd KJ; Lim S; Engle JT; Phillips S; Tan B; Wang-Gillam A; Bognar C; Chu W; Zhou D; Mach RH; Laforest R; Chen DL
Radiology; 2017 Feb; 282(2):453-463. PubMed ID: 27841728
[TBL] [Abstract][Full Text] [Related]
8. Two experts and a newbie: [
Stotz S; Kinzler J; Nies AT; Schwab M; Maurer A
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):834-846. PubMed ID: 34486071
[TBL] [Abstract][Full Text] [Related]
9. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.
Makvandi M; Pantel A; Schwartz L; Schubert E; Xu K; Hsieh CJ; Hou C; Kim H; Weng CC; Winters H; Doot R; Farwell MD; Pryma DA; Greenberg RA; Mankoff DA; Simpkins F; Mach RH; Lin LL
J Clin Invest; 2018 May; 128(5):2116-2126. PubMed ID: 29509546
[TBL] [Abstract][Full Text] [Related]
10. Solid phase radiosynthesis of an olaparib derivative using 4-[
Xu J; Chen H; Rogers BE; Katzenellenbogen JA; Zhou D
Nucl Med Biol; 2022; 114-115():65-70. PubMed ID: 36193598
[TBL] [Abstract][Full Text] [Related]
11. Preliminary evaluation of a novel
Zhou D; Xu J; Mpoy C; Chu W; Kim SH; Li H; Rogers BE; Katzenellenbogen JA
Nucl Med Biol; 2018 Nov; 66():26-31. PubMed ID: 30195072
[TBL] [Abstract][Full Text] [Related]
12. Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted
Young AJ; Pantel AR; Viswanath V; Dominguez TL; Makvandi M; Lee H; Li S; Schubert EK; Pryma DA; Farwell MD; Mach RH; Simpkins F; Lin LL; Mankoff DA; Doot RK
J Nucl Med; 2022 Jan; 63(1):44-50. PubMed ID: 33863820
[TBL] [Abstract][Full Text] [Related]
13. PARP-1 Expression Quantified by [
Sander Effron S; Makvandi M; Lin L; Xu K; Li S; Lee H; Hou C; Pryma DA; Koch C; Mach RH
Cancer Biother Radiopharm; 2017 Feb; 32(1):9-15. PubMed ID: 28118040
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, and Evaluation of [
Zheng W; Huang Y; Xie Y; Yang T; Cheng X; Chen H; Li C; Jiang Z; Yu Z; Li Z; Zhang L; Yuan L; Liu Y; Liang Y; Wu Z
Mol Pharm; 2024 Apr; ():. PubMed ID: 38606716
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Rajawat J; Shukla N; Mishra DP
Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
[TBL] [Abstract][Full Text] [Related]
16. Safety and Feasibility of PARP1/2 Imaging with
Schöder H; França PDS; Nakajima R; Burnazi E; Roberts S; Brand C; Grkovski M; Mauguen A; Dunphy MP; Ghossein RA; Lyashchenko SK; Lewis JS; O'Donoghue JA; Ganly I; Patel SG; Lee NY; Reiner T
Clin Cancer Res; 2020 Jul; 26(13):3110-3116. PubMed ID: 32245901
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Wang X; Shi Y; Huang D; Guan X
Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson's Disease.
Puentes LN; Lengyel-Zhand Z; Reilly SW; Mach RH
Mol Neurobiol; 2021 Aug; 58(8):3641-3652. PubMed ID: 33788167
[TBL] [Abstract][Full Text] [Related]
19. Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo.
Anderson RC; Makvandi M; Xu K; Lieberman BP; Zeng C; Pryma DA; Mach RH
Nucl Med Biol; 2016 Dec; 43(12):752-758. PubMed ID: 27689533
[TBL] [Abstract][Full Text] [Related]
20. PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma.
Jannetti SA; Carlucci G; Carney B; Kossatz S; Shenker L; Carter LM; Salinas B; Brand C; Sadique A; Donabedian PL; Cunanan KM; Gönen M; Ponomarev V; Zeglis BM; Souweidane MM; Lewis JS; Weber WA; Humm JL; Reiner T
J Nucl Med; 2018 Aug; 59(8):1225-1233. PubMed ID: 29572254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
